PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF- кB pathway activity and DNA damage response induced by Idarubicin : PARP-1 inhibitors attenuate DNA damage response

Idarubicin (IDA), an anthracycline antineoplastic drug, is commonly used in the treatment of acute myeloid leukemia (AML) with reasonable response rates and clinical benefits. However, some patients still relapse, or do not respond, and suffer high fatality rates. Recent studies have shown that over...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Bo, Li, Anna, Fu, Huan, Kong, Chunfang, Liu, Tingting, Zhu, Qingqing, Zhang, Yue, Zhang, Zixia, Chen, Chen, Jin, Chenghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909352/
https://www.ncbi.nlm.nih.gov/pubmed/35130631
http://dx.doi.org/10.3724/abbs.2021011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909352/
https://www.ncbi.nlm.nih.gov/pubmed/35130631
http://dx.doi.org/10.3724/abbs.2021011

Ejemplares similares